- Home
- EDIT vs PGP Comparison
EDIT vs PGP Comparison
Compare EDIT & PGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- PGP
- Stock Information
- Founded
- EDIT 2013
- PGP 2003
- Country
- EDIT United States
- PGP United States
- Employees
- EDIT N/A
- PGP N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- PGP Finance Companies
- Sector
- EDIT Health Care
- PGP Finance
- Exchange
- EDIT Nasdaq
- PGP Nasdaq
- Market Cap
- EDIT 99.9M
- PGP 89.0M
- IPO Year
- EDIT 2016
- PGP N/A
- Fundamental
- Price
- EDIT $1.21
- PGP $7.94
- Analyst Decision
- EDIT Buy
- PGP
- Analyst Count
- EDIT 14
- PGP 0
- Target Price
- EDIT $8.08
- PGP N/A
- AVG Volume (30 Days)
- EDIT 2.7M
- PGP 39.8K
- Earning Date
- EDIT 02-26-2025
- PGP 01-01-0001
- Dividend Yield
- EDIT N/A
- PGP 10.84%
- EPS Growth
- EDIT N/A
- PGP N/A
- EPS
- EDIT N/A
- PGP N/A
- Revenue
- EDIT $61,759,000.00
- PGP N/A
- Revenue This Year
- EDIT N/A
- PGP N/A
- Revenue Next Year
- EDIT N/A
- PGP N/A
- P/E Ratio
- EDIT N/A
- PGP N/A
- Revenue Growth
- EDIT 150.95
- PGP N/A
- 52 Week Low
- EDIT $1.12
- PGP $5.83
- 52 Week High
- EDIT $11.58
- PGP $7.81
- Technical
- Relative Strength Index (RSI)
- EDIT 34.86
- PGP 55.47
- Support Level
- EDIT $1.15
- PGP $7.55
- Resistance Level
- EDIT $1.27
- PGP $7.95
- Average True Range (ATR)
- EDIT 0.10
- PGP 0.14
- MACD
- EDIT 0.04
- PGP 0.03
- Stochastic Oscillator
- EDIT 21.11
- PGP 97.50
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About PGP Pimco Global StocksPlus & Income Fund of Beneficial Interest
PIMCO Global Stocksplus & Income Fund is a closed-end management investment company. The objective of the fund is to seek a total return comprised of current income, current gains, and long-term capital appreciation. The fund invests a majority of the fund's net assets in a combination of securities and instruments that provide exposure to stocks and or produce income.